Inventor · disambiguated record
Ashok K. Gupta
Also filed as: GUPTA ASHOK · GUPTA ASHOK K · GUPTA ASHOK KUMAR
19 granted patents·13 pending applications·646 citations·filing 2002–2025
97Inventor score
Top patents by PatentIndex Score
32 records- 0198US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 0298US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 0398US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 0498US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 0598US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 0698US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 0798US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0898US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0998US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 1098US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 1198US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 1297US10584170B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 10, 2020·23 cites·27 claims
- 1397US10577423B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 3, 2020·23 cites·27 claims
- 1497US10316090B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·29 cites·27 claims
- 1597US9212224B2Antibodies that bind PD-L1 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 15, 2015·135 cites·2 claims
- 1693US9789182B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 17, 2017·11 cites·15 claims
- 1792US2024417471A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1886US2024002512A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1986US2024034793A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2084US10688180B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 23, 2020·2 cites·15 claims
- 2175US2020308282A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2268US2022332828A1Anti-pd-l1 antibody treatment of bladder cancerMEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 2367US10494433B2Combination of anti-KIR and anti-CS1 antibodies to treat multiple myelomaBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Dec 3, 2019·1 cites·14 claims
- 2455US2019359715A1Anti-pd-l1 antibody treatment of bladder cancerMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 2554US2025388678A1Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder CancerASTRAZENECA AB·Filed 2025·Application pending·0 cites
- 2651US2004209858A1Cycloalkylamides and their therapeutic applicationsFiled 2003·Application pending·0 cites
- 2751US2015290316A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2850US2025367285A1Methods of treating melanoma using tebentafusp and immune checkpoint inhibitorsABDULLAH SHAAD·Filed 2023·Application pending·0 cites
- 2949US2018099045A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3046US2013156768A1Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2011·Application pending·0 cites
- 3142US12209126B2Treatment of cancerMEDIMMUNE LTD·Filed 2019·Granted Jan 28, 2025·0 cites·18 claims
- 3240US2004077618A1Cycloalkylamides and their therapeutic applicationsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ashok K. Gupta files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →